Skip to main content
. Author manuscript; available in PMC: 2014 Sep 5.
Published in final edited form as: Sci Transl Med. 2014 Mar 5;6(226):226ra32. doi: 10.1126/scitranslmed.3008095

Figure 6. Anti-tumor activity of NDV combination therapy depends on CD8+ and NK cells and type I and type II interferons.

Figure 6

(A–C) Animals were treated as described in Fig. 3A with or without depleting antibodies for CD4+, CD8+, NK cells, or IFNγ. (A) Growth of injected tumors. (B) Growth of distant tumors. (C) Long-term survival. (D–F) IFNAR−/− or age-matched C57BL/6 mice (BL/6) were treated as described in Fig. 3A and monitored for tumor growth. (D) Growth of injected tumors. (E) Growth of distant tumors. (F) Long-term survival. Data for all panels represent cumulative results from 2 independent experiments with n=3–10 per group. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.